Scarica l'app Stockscreener
2.04
2.51%
0.05
Dopo l'orario di chiusura:
2.03
-0.01
-0.49%
Precedente Chiudi:
$1.99
Aprire:
$2.03
Volume 24 ore:
323.87K
Relative Volume:
0.87
Capitalizzazione di mercato:
$87.42M
Reddito:
-
Utile/perdita netta:
$-77.27M
Rapporto P/E:
-1.019
EPS:
-2.0019
Flusso di cassa netto:
$-66.29M
1 W Prestazione:
-0.97%
1M Prestazione:
+17.24%
6M Prestazione:
+22.89%
1 anno Prestazione:
+25.15%
Intervallo 1D:
$1.96
$2.06
Intervallo di 1 settimana:
$1.96
$2.175
Portata 52W:
$1.27
$3.56
Acrivon Therapeutics Inc Stock (ACRV) Company Profile
Nome
Acrivon Therapeutics Inc
Settore
Industria
Telefono
617-207-8979
Indirizzo
480 ARSENAL WAY, SUITE 100, WATERTOWN
Compare ACRV vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ACRV
Acrivon Therapeutics Inc
|
2.04 | 85.28M | 0 | -77.27M | -66.29M | -2.0019 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Acrivon Therapeutics Inc Stock (ACRV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-05 | Ripresa | Piper Sandler | Overweight |
| 2025-01-31 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2024-09-16 | Aggiornamento | Ladenburg Thalmann | Neutral → Buy |
| 2024-04-29 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2024-03-01 | Iniziato | JMP Securities | Mkt Outperform |
| 2023-12-15 | Ripresa | Jefferies | Buy |
| 2023-10-05 | Iniziato | Maxim Group | Buy |
| 2023-06-02 | Iniziato | Oppenheimer | Outperform |
| 2023-05-08 | Iniziato | BMO Capital Markets | Outperform |
| 2023-04-27 | Iniziato | Ladenburg Thalmann | Buy |
| 2023-04-20 | Iniziato | H.C. Wainwright | Buy |
| 2022-12-12 | Iniziato | Cowen | Outperform |
| 2022-12-12 | Iniziato | Jefferies | Buy |
| 2022-12-12 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Acrivon Therapeutics Inc Borsa (ACRV) Ultime notizie
Acrivon Therapeutics at 12th annual Cantor Fitzgerald conference: platform push - Investing.com Canada
Acrivon Therapeutics, Inc. (ACRV) Just Flashed Golden Cross Signal: Do You Buy? - Yahoo Finance
Acrivon Therapeutics to Present at the 2026 Cantor Global Healthcare Conference - The Manila Times
acrivon appoints michaela levin as chief business officer By Investing.com - Investing.com Nigeria
Acrivon Therapeutics Names Michaela Levin Chief Business Officer - citybiz
acrivon appoints michaela levin as chief business officer - Investing.com
Acrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business Officer - GlobeNewswire
ACRV Q2 2026 Earnings: Narrower-Than-Expected Loss in a Pre-Revenue QuarterProfit Margin Analysis - vinanet.vn
Acrivon (NASDAQ: ACRV) CEO sells 14K shares to cover RSU taxes - Stock Titan
Acrivon (NASDAQ: ACRV) CEO may sell stock from vested RSUs - Stock Titan
Here's Why Acrivon Therapeutics, Inc. (ACRV) is a Great Momentum Stock to Buy - Yahoo Finance
Acrivon Therapeutics (ACRV) CLO sells 185 shares for taxes - Stock Titan
Acrivon Therapeutics (ACRV) insider offloads 400 shares for taxes - Stock Titan
Acrivon Therapeutics (ACRV) COO’s tax sale leaves 146,349 shares - Stock Titan
Acrivon (NASDAQ: ACRV) chiefs sell shares to cover RSU taxes - Stock Titan
Acrivon (ACRV) Results Breakdown: EPS Exceeds Its Estimate in the Latest Session; Post-Report: The Stock Closes Near Unchanged on the DayFull Year Guidance - vinanet.vn
ACRV Q1 2026 Earnings: Narrower-than-Expected Loss Lifts Shares 5.9%Capex Guidance - vinanet.vn
Acrivon Therapeutics Inc (ACRV) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Q3 EPS Estimate for Acrivon Therapeutics Raised by Analyst - MarketBeat
ACRV Q1 2026 Earnings: Loss Narrower Than Expected, Stock Advances 5.41%Forward EPS Estimate - Vinanet
Analysts Offer Insights on Healthcare Companies: Acrivon Therapeutics, Inc. (ACRV) and Belite Bio, Inc. ADR (BLTE) - The Globe and Mail
HC Wainwright Has Bullish Estimate for ACRV FY2030 Earnings - MarketBeat
Piper Sandler Maintains Acrivon Therapeutics(ACRV.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Sands Capital group (NASDAQ: ACRV) discloses 5.3% Acrivon ownership in 13G/A - Stock Titan
Acrivon Therapeutics: Buy Rating Reaffirmed as Pipeline Progress Supports Attractive Valuation; $19 Price Target Maintained - TipRanks
Acrivon Therapeutics, Inc. (ACRV) Stock Price, News, Quote & History - Yahoo! Finance Canada
Acrivon Therapeutics Q2 2026: Net loss narrows to $18.0M, cash at $90.0M - scanx.trade
Acrivon Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Acrivon Therapeutics (NASDAQ:ACRV) Releases Quarterly Earnings Results, Beats Expectations By $0.06 EPS - MarketBeat
Acrivon Therapeutics (ACRV) Slips to $1.72, Holds Support at $1.63Imbalance Zone - Vinanet
Acrivon Therapeutics Q2 net loss narrows as costs decline - TradingView
BRIEF-Acrivon Therapeutics, Inc Q2 Income From Operations USD -18.668 Million - TradingView
Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts - GlobeNewswire
Acrivon Therapeutics Inc (ACRV) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
Acrivon Therapeutics, Inc. expected to post a loss of 50 cents a shareEarnings Preview - TradingView
Acrivon Therapeutics Inc (ACRV) Stock News Today - TradingKey
(ACRV) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Acrivon Therapeutics, Inc. (ACRV) CFO sells 1,142 shares to cover taxes - Stock Titan
Acrivon Therapeutics: Buy Rating Reiterated as ACR-2316’s Emerging Clinical Profile and Differentiated Safety Support Unchanged $19 Price Target - TipRanks
Acrivon advances cancer drug ACR-2316 to dose expansion phase By Investing.com - Investing.com Nigeria
Acrivon advances cancer drug ACR-2316 to dose expansion phase - Investing.com
Acrivon Therapeutics (ACRV) Projected to Post Earnings on Wednesday - MarketBeat
Acrivon Advances ACR-2316, a Potential First-in-Class - GlobeNewswire
Acrivon Therapeutics (ACRV) Holds Near Support as Shares Edge Higher in Quiet SessionETF Creation Redemption - vinanet.vn
ACRV|Acrivon Therapeutics Inc|Price:1.550|Chg%:+0.050 - TradingKey
Acrivon Therapeutics (ACRV) Dips 1.3% to $1.50 as Biotech Volatility ContinuesShakeout Pattern - vinanet.vn
Acrivon Therapeutics (ACRV) Edges Higher as Biotech Stock Tests Key Resistance at $1.63MFI Oversold - vinanet.vn
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Short Interest Down 47.6% in July - MarketBeat
ACRV Stock Price, Quote & Chart - ChartMill
Acrivon Therapeutics Inc (ACRV) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Acrivon Therapeutics Inc (ACRV) Balance Sheet - TradingKey
Acrivon Therapeutics Inc Azioni (ACRV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):